Figure 4.

Effect of Bevacizumab on serum cytokines levels. Cytokine serum levels were assessed in the two treatment arms: chemotherapy (blue), chemotherapy + Bev (green), and at four different time points, 0, 12, 25 and 31 weeks. To find the most relevant and significant differences between the two arms, we first tested for global differences using ANOVA (Table 2), and only for the significant values showing a significant result in the global three-way ANOVA (FDR-adjusted P < 0.1) (and TNF-alpha) further tested for significant difference at each time point using t-test. For (A) VEGF-A, (B) IL-12, (C) IP-10, and (D) IL-10, we found a global difference between their levels when comparing the two arms (ANOVA P < 0.05) and further identified significant differences at the indicated time points: * P < 0.05, ** P < 0.01, *** P < 0.001. Error bars represent ± 1 standard deviation.